A report by the IQVIA Institute for Human Data Science.
-
Cancer care during COVID-19, part 1: dramatic fall in screening and monitoring -
Statin use may lower the risk of melanoma recurrence The risk of recurrence was significantly lower in men and those with ulcerated melanoma.
-
AACR 2020 – Does the dosing schedule of BRAF and MEK inhibitor combinations influence resistance? The SWOG S1320 trial compared continuous and intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma
-
AACR 2020 – Combining immune and targeted therapy in advanced melanoma with BRAFV600 mutations The IMspire150 trial evaluated a new combination strategy in treatment-naive patients by adding the immune checkpoint inhibitor atezolizumab to the targeted therapy with cobimetinib and vemurafenib.
-
EMA concludes safety review of topical ingenol mebutate Risks outweigh benefits, says review.
-
Advanced cancer mediates elevated stroke risk after chemo Adjusting for site and stage eliminate the link between chemotherapy and stroke.
-
COVID-19: NCCN recommends deferring nonurgent treatments for skin cancer The recommendations will help conserve resources during the pandemic.
-
Blood test detects more than 50 cancer types The test identifies tissue of origin too.
-
France publishes guidelines for protecting cancer patients from SARS-CoV-2 Cancer patients may be at high risk for complications, especially those with lymphopenia, neutropenia.
-
Hospitalized cancer patients may face 2-fold greater risk of SARS-CoV-2 transmission Findings from Wuhan, China, suggest aggressive measures to curtail frequency of hospital visits.
-
Metastatic melanoma: response and relapse after stopping anti-PD-1 therapy Previous studies have shown good outcomes in patients achieving CR.
-
An increased incidence of skin malignancies has been reported.
-
Melanoma: is there any association with BMI and height? Results from a 2-sample Mendelian randomisation analysis.
-
Systemic therapies refine surgical treatment of cancer ASCO lists notable 2019 studies in melanoma, renal, and pancreatic cancer.